The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2023, Volume and Issue: 20(12), P. 764 - 783

Published: Aug. 15, 2023

Language: Английский

---

Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults

Liver International, Journal Year: 2024, Volume and Issue: 44(4), P. 1051 - 1060

Published: Jan. 31, 2024

Abstract Background & Aims Following the classification of metabolic dysfunction‐associated fatty liver disease (MAFLD), non‐alcoholic (NAFLD) has recently been redefined again as steatotic (MASLD). However, distinctions in characteristics and mortality outcomes between NAFLD, MAFLD MASLD remain unclear. Methods We analysed data from 7519 participants third National Health Nutrition Examination Surveys United States (US) their linked until 2019. Survey weight‐adjusted multivariable Cox proportional model was used to study over three terms. Results The prevalence 18.5%, 19.3% 20.8%, respectively. Most individuals with NAFLD (94.5%) or (100%) can be classified MASLD, while a relatively low percentage those were also diagnosed either (84.1%) (92.7%). During median follow‐up 26.9 years, both associated increased risk all‐cause (adjusted hazard ratio [aHR] 1.18, 95% CI 1.04–1.33 1.19, 1.06–1.34, respectively), this association mainly observed NAFLD−/MASLD+ subgroups. not mortality. all terms an advanced fibrosis (aHR: 1.71–1.81). Subgroup analyses showed that higher for among older adults (≥65 year), non‐Hispanic whites without diabetes. Conclusions Both MALFD risk, but identified greater number compared MAFLD.

Language: Английский

---

Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(6), P. 930 - 940

Published: July 4, 2024

Language: Английский

---

Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction

Gastroenterology, Journal Year: 2024, Volume and Issue: 167(2), P. 357 - 367.e9

Published: March 19, 2024

There is an unmet need for noninvasive tests to improve case-finding and aid primary care professionals in referring patients at high risk of liver disease.

Language: Английский

---

Comparison of mortality outcomes in individuals with MASLD and/or MAFLD

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 80(2), P. e62 - e64

Published: Aug. 12, 2023

Language: Английский

---

Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings

Hepatology, Journal Year: 2023, Volume and Issue: 79(6), P. 1393 - 1400

Published: Nov. 1, 2023

In relation to the new umbrella terminology for steatotic liver disease (SLD), we aimed elucidate prevalence, distribution, and clinical characteristics of SLD subgroups in primary care setting.

Language: Английский

---

Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 80(2), P. e53 - e54

Published: July 28, 2023

Language: Английский

---

Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach

Circulation, Journal Year: 2024, Volume and Issue: 151(1), P. 98 - 119

Published: Dec. 26, 2024

There is a new awareness of the widespread nature metabolic dysfunction–associated steatotic liver disease (MASLD) and its connection to cardiovascular (CVD). This has catalyzed collaboration between cardiologists, hepatologists, endocrinologists, wider multidisciplinary team address need for earlier identification those with MASLD who are at increased risk CVD. The overlap in pathophysiologic processes parallel prevalence CVD, syndrome, highlight multisystem consequences poor cardiovascular–liver–metabolic health. Metabolic dysfunction associated insulin resistance, together predilection ectopic fat deposition surrounding tissues, elevated endothelial dysfunction, systemic inflammatory response, epicardium. complex pathophysiology can accelerate atherogenic dyslipidemia, atherogenesis, diastolic valvular calcification, cardiac arrhythmias. Despite mounting evidence mechanistic pathways underpinning current recommendations have not clearly focused upon as factor or target intervention We brought diverse range international experts committed promoting health related outcomes across globe. overarching goal this document offer construct clinicians field regards (1) diagnosis screening through use noninvasive serum imaging tests; (2) CVD all individuals regardless established atherosclerotic factors; (3) approach management respect prevention lifestyle, well pharmacologic surgical strategies. To achieve this, modified Delphi method was applied series evidence-based quality standard been identified.

Language: Английский

---

Metabolic and alcohol-associated liver disease (MetALD): a representation of duality

npj gut and liver., Journal Year: 2025, Volume and Issue: 2(1)

Published: Jan. 10, 2025

MetALD is a recently coined term that refers to systemic entity describe patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and simultaneous moderate alcohol consumption. The deleterious association of risk factors synergistically increases the development steatohepatitis, fibrosis, hepatocellular carcinoma (HCC). Despite its increasing incidence, pathophysiological mechanisms triggering damage in remain unclear. This review aims summarize prevalence, pathophysiology MetALD, taking into account latest clinical translational aspects.

Language: Английский

---

Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake

Journal of Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 39(11), P. 2456 - 2463

Published: Aug. 22, 2024

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has become a leading cause of chronic worldwide. A new entity termed MetALD also been described is defined as individuals with MASLD increased alcohol intake. However, the natural history compared unknown. We aimed to compare longitudinal outcomes in patients versus MetALD. Methods This study was performed using data from National Health Nutrition Examination Survey 2011 2018. (defined by United States Fatty Liver Index > 30) who met cardiometabolic criteria including body mass index (BMI) 25 (BMI 23 Asians), hypertension, diabetes mellitus, dyslipidemia, hypertriglyceridemia were included. intake (3–6 standard drinks per day males; 2–5 females). comparison overall, cardiovascular, cancer‐related, other causes mortality performed. Results total 2838 2557 included median follow‐up time 56 months. at risk cancer‐related (hazard ratio 1.32; 95% confidence interval 1.14–1.53; P < 0.01). there no significant difference mortality. Conclusions Patients higher for than MASLD. Close attention regular cancer surveillance accurate classification consumption diagnosed warranted help improve patient care outcome.

Language: Английский

---